CD19 chimeric antigen receptor T-cell therapy following autologous stem cell transplantation against relapsed or refractory Burkitt lymphoma/leukemia: A case report and literature review

CD19 chimeric antigen receptor T-cell therapy following autologous stem cell transplantation against relapsed or refractory Burkitt lymphoma/leukemia: A case report and literature review

Burkitt lymphoma or leukemia (BL) is a highly aggressive non-Hodgkin lymphoma. Older age (over 60 years old) and the presence of high-risk factors (such as abdominal mass, high levels of the serum lactic dehydrogenase, Ann Arbor stage II-IV and so on) usually predict a poorer outcome. Chimeric antig...

Full description

Bibliographic Details
Main Authors: Mingyu Ye, Lei Gao, Tao Wang, Jiechen Yu, Jiaping Gui, Jianmin Yang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Frontiers in Oncology
Subjects:
Burkitt lymphoma
leukemia
CD19
chimeric antigen receptor T-cell
autologous stem cell transplantation
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.932254/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.932254/full

Similar Items